These tumors show molecular features that may predict the sensitivity to PARP inhibition, such as the high prevalence of HRD71; by contrast, the anti PD-L1 durvalumab demonstrated a meaningful activity in endometrial cancer with deficient DNA mismatch repair in the phase II PHAEDRA trial.72 Here, PARP1 is linked to endometrial cancer.